Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)30.97
  • Today's Change0.77 / 2.55%
  • Shares traded23.67k
  • 1 Year change+93.56%
  • Beta0.8628
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's royalty portfolio includes OJEMDA (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, mezagitamab (TAK-079), acimtamig (AFM13), AB054, ficlatuzumab (AV-299), COM902, vosaroxin, aldoxorubicin, INCAGN02385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], CMP-001 (vidutolimod), NTM-1631, NTM-1634, NTM-1633, NTM-1632, NIR178, MK-4830, AFM24, INCAGN01949, AB101, and CFZ533 (iscalimab).

  • Revenue in USD (TTM)15.24m
  • Net income in USD-25.10m
  • Incorporated2011
  • Employees13.00
  • Location
    XOMA Royalty Corp2200 Powell Street, Suite 310EMERYVILLE 94608United StatesUSA
  • Phone+1 (510) 204-7239
  • Fax+1 (302) 655-5049
  • Websitehttps://www.xoma.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
XOMA:NMQ since
announced
Transaction
value
Kinnate Biopharma IncDeal completed16 Feb 202416 Feb 2024Deal completed39.63%99.33m
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Rezolute Inc0.00-68.46m323.32m59.00--2.46-----1.33-1.330.002.270.00----0.00-53.39-50.36-56.66-53.25------------0.00-------32.19------
Aldeyra Therapeutics Inc0.00-37.87m328.01m10.00--3.34-----0.6387-0.63870.001.650.00----0.00-26.89-36.79-31.76-40.77------------0.1342------39.47------
Design Therapeutics Inc0.00-50.53m330.10m57.00--1.26-----0.8982-0.89820.004.610.00----0.00-17.39---17.96--------------0.00-------5.61------
Codexis Inc64.45m-62.09m332.02m174.00--4.52--5.15-0.878-0.8780.91490.9020.42597.033.62370,379.30-41.03-17.13-54.21-20.2375.9677.29-96.35-37.043.15--0.2806---49.392.97-126.96--9.80--
iTeos Therapeutics Inc35.00m-108.14m338.56m157.00--0.51--9.67-3.00-3.000.951718.180.0481--1.52222,929.90-14.865.84-15.557.02-----308.9622.09----0.000.00-95.29---216.54--68.45--
enGene Holdings Inc0.00-123.44m349.30m33.00--1.52-----4.77-4.770.005.210.00----0.00-78.13---84.20-------------3.140.0906-------260.87------
Lyell Immunopharma Inc54.00k-210.26m358.79m224.00--0.5512--6,644.33-0.8297-0.82970.00022.210.00007----241.07-28.23---29.53-------389,368.50------0.00---99.85---28.13------
Sutro Biopharma Inc169.36m-124.45m359.00m304.00--2.36--2.12-1.84-1.842.561.860.3551--19.98560,791.40-26.09-25.48-32.89-29.75-----73.48-113.71----0.00--126.8431.9610.41--22.61--
XOMA Royalty Corp15.24m-25.10m362.49m13.00--3.61--23.79-2.22-2.221.178.580.0826--21.361,172,231.00-9.88-4.55-10.62-4.94-----119.61-31.87----0.5471---21.06-2.13-105.10--23.16--
Jasper Therapeutics Inc0.00-62.44m370.53m45.00--3.69-----5.10-5.100.006.640.00----0.00-52.45---57.00--------------0.00-------71.06------
Compass Pathways PLC (ADR)0.00-144.32m372.89m186.00--1.93-----2.19-2.190.002.820.00----0.00-52.83-40.85-57.18-44.48------------0.1337-------29.46---12.68--
Northwest Biotherapeutics Inc1.65m-75.55m380.59m25.00------231.36-0.0644-0.06440.0014-0.0470.0581----65,800.00-260.06-381.58---------4,479.03-6,479.25---14.10----14.8036.2138.71--77.88--
SAGE Therapeutics Inc106.40m-337.59m386.00m487.00--0.6995--3.63-5.58-5.581.769.020.1354--5.24218,478.40-42.95-21.88-48.97-23.3091.7599.63-317.29-131.50----0.00--1,024.84-0.8606-1.63---28.01--
Voyager Therapeutics Inc143.77m9.02m388.82m162.0046.471.1627.992.700.15340.15342.756.160.3825--43.56887,462.902.400.63782.710.8203----6.281.30----0.000.00511.16101.01385.14---5.43--
ProQR Therapeutics NV20.05m-23.09m399.26m157.00--9.02--19.91-0.2839-0.28390.24640.4180.1406----127,701.20-15.98-35.51-20.63-40.51-----113.62-926.31----0.3687--118.5110.5856.35--34.45--
Data as of Nov 08 2024. Currency figures normalised to XOMA Royalty Corp's reporting currency: US Dollar USD

Institutional shareholders

57.27%Per cent of shares held by top holders
HolderShares% Held
BVF Partners LPas of 30 Jun 20243.63m31.05%
Fidelity Management & Research Co. LLCas of 30 Jun 20241.10m9.36%
BlackRock Fund Advisorsas of 30 Jun 2024470.36k4.02%
The Vanguard Group, Inc.as of 30 Jun 2024402.79k3.44%
Stonepine Capital Management LLCas of 30 Jun 2024250.13k2.14%
Opaleye Management, Inc.as of 30 Jun 2024250.00k2.14%
Geode Capital Management LLCas of 30 Jun 2024181.60k1.55%
Morgan Stanley Investment Management, Inc.as of 30 Jun 2024157.22k1.34%
SSgA Funds Management, Inc.as of 30 Jun 2024141.10k1.21%
TLS Advisors LLCas of 30 Jun 2024120.37k1.03%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.